Mereo BioPharma
Generated by Meeveem AI
"Advancing clinical-stage therapies for rare diseases with limited treatment options"
London
•11 - 50 Employees
•Biotechnology
About Mereo BioPharma
Mereo BioPharma acquires and develops promising rare disease therapeutics that have been de-prioritised by larger pharmaceutical companies. The company focuses on late-stage clinical programs in osteogenesis imperfecta and Alpha-1 Antitrypsin Deficiency-associated Lung Disease, navigating complex regulatory pathways to bring these therapies closer to the people who need them most. Founded in 2015, Mereo operates with a capital-efficient model, forming strategic partnerships while retaining commercial rights in key markets. The team works closely with patient communities, physicians, and healthcare systems, ensuring that development decisions are informed by the lived experiences of people with rare conditions.
39
Team Members
2015
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A future where people and families living with rare diseases have access to therapies that can transform their lives, especially those with few or no treatment options.
Our Mission
At Mereo, our mission is to deliver impactful therapies to treat rare diseases with limited or no treatment options.